AU2021381384A1 - Compositions and methods for optimized peptide vaccines - Google Patents

Compositions and methods for optimized peptide vaccines Download PDF

Info

Publication number
AU2021381384A1
AU2021381384A1 AU2021381384A AU2021381384A AU2021381384A1 AU 2021381384 A1 AU2021381384 A1 AU 2021381384A1 AU 2021381384 A AU2021381384 A AU 2021381384A AU 2021381384 A AU2021381384 A AU 2021381384A AU 2021381384 A1 AU2021381384 A1 AU 2021381384A1
Authority
AU
Australia
Prior art keywords
peptide
seq
hla
sequence
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021381384A
Other languages
English (en)
Inventor
Brandon CARTER
David Gifford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Think Therapeutics Inc
Original Assignee
Think Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/100,630 external-priority patent/US11058751B1/en
Priority claimed from US17/114,237 external-priority patent/US11161892B1/en
Priority claimed from US17/389,875 external-priority patent/US11421015B2/en
Application filed by Think Therapeutics Inc filed Critical Think Therapeutics Inc
Publication of AU2021381384A1 publication Critical patent/AU2021381384A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021381384A 2020-11-20 2021-11-19 Compositions and methods for optimized peptide vaccines Pending AU2021381384A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US17/100,630 US11058751B1 (en) 2020-11-20 2020-11-20 Compositions for optimized RAS peptide vaccines
US17/100,630 2020-11-20
US17/114,237 2020-12-07
US17/114,237 US11161892B1 (en) 2020-12-07 2020-12-07 Method of compact peptide vaccines using residue optimization
US17/336,960 US11235039B1 (en) 2020-11-20 2021-06-02 Immunogenic compositions comprising nucleic acids for RAS peptides
US17/336,960 2021-06-02
US17/389,875 US11421015B2 (en) 2020-12-07 2021-07-30 Method of compact peptide vaccines using residue optimization
US17/389,875 2021-07-30
US202163249235P 2021-09-28 2021-09-28
US63/249,235 2021-09-28
PCT/US2021/060013 WO2022109220A1 (en) 2020-11-20 2021-11-19 Compositions and methods for optimized peptide vaccines

Publications (1)

Publication Number Publication Date
AU2021381384A1 true AU2021381384A1 (en) 2023-06-22

Family

ID=81708071

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021381384A Pending AU2021381384A1 (en) 2020-11-20 2021-11-19 Compositions and methods for optimized peptide vaccines

Country Status (5)

Country Link
EP (1) EP4247401A4 (enExample)
JP (1) JP7829242B2 (enExample)
AU (1) AU2021381384A1 (enExample)
CA (1) CA3202227A1 (enExample)
WO (1) WO2022109220A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240131133A1 (en) * 2022-10-10 2024-04-25 Think Therapeutics, Inc. Compositions and methods for optimized kras peptide vaccines
CN116130005B (zh) * 2023-01-30 2023-06-16 深圳新合睿恩生物医疗科技有限公司 多表位疫苗的串联设计方法及装置、设备、存储介质

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884893B2 (en) * 2012-05-21 2018-02-06 Distributed Bio, Inc. Epitope focusing by variable effective antigen surface concentration
WO2016154047A2 (en) * 2015-03-20 2016-09-29 Memorial Sloan-Kettering Cancer Center Monoclonal antigen-binding proteins to intracellular oncogene products
RU2719033C2 (ru) * 2015-04-23 2020-04-16 Нантомикс, Ллс Способ получения фармацевтического агента для иммунотерапии рака
EP3294324A1 (en) * 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
CA2986235A1 (en) * 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
EP4159751A1 (en) 2016-08-02 2023-04-05 The United States of America, as represented by the Secretary, Department of Health and Human Services Anti-kras-g12d t cell receptors
EP3532070A1 (en) * 2016-10-26 2019-09-04 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
EP3576764A4 (en) 2017-02-03 2020-12-16 The Medical College of Wisconsin, Inc. KRAS PEPTIDIC VACCINE COMPOSITIONS AND METHOD OF USE
CN108395479B (zh) 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
WO2019246286A1 (en) * 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
TW202039534A (zh) * 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
WO2020210202A1 (en) 2019-04-11 2020-10-15 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
US11058751B1 (en) * 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11161892B1 (en) * 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization

Also Published As

Publication number Publication date
EP4247401A1 (en) 2023-09-27
JP7829242B2 (ja) 2026-03-13
EP4247401A4 (en) 2025-06-11
WO2022109220A1 (en) 2022-05-27
JP2023551204A (ja) 2023-12-07
CA3202227A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
US11464837B2 (en) Immunogenic compositions comprising nucleic acids for RAS peptides
AU2022264493A1 (en) Compositions and method for optimized peptide vaccines using residue optimization
US11161892B1 (en) Method of compact peptide vaccines using residue optimization
US20250222087A1 (en) Compositions for optimized bcr-abl peptide vaccines
JP7829242B2 (ja) 最適化ペプチドワクチンの組成物および方法
US20240383963A1 (en) Method of compact peptide vaccines using residue optimization
Odales et al. Antitumor efficacy of MUC1-derived variable epitope library treatments in a mouse model of breast cancer
CN113395976A (zh) 良性肿瘤的预防或治疗药
US20250333448A1 (en) Compositions for optimized influenza peptide vaccines
US20240131133A1 (en) Compositions and methods for optimized kras peptide vaccines
US20250235526A1 (en) Compositions and methods for optimized hiv peptide vaccines
US20260041763A1 (en) Compositions and methods for optimized covid peptide vaccines
US20240269250A1 (en) Compositions and method for optimized peptide vaccines using residue optimization
HK40100731A (zh) 用於优化的肽疫苗的组合物和方法
WO2025064339A1 (en) Compositions and methods for optimized peptide vaccines
HK40101953A (zh) 利用残基优化技术优化肽疫苗的组合物和方法